Indolocarbazoles as host-directed therapeutics against intracellular infections by methicillin-resistant Staphylococcus aureus
Journal of Antimicrobial Chemotherapy · 2025
DOI: 10.1093/jac/dkaf198 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Robin H G A van den Biggelaar und 4 weiteren Autor:innen. Beteiligte Einrichtung: Leiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands. Hauptthemen laut MEDLINE: Methicillin-Resistant Staphylococcus aureus, Carbazoles, Anti-Bacterial Agents, Staphylococcal Infections. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and objectives Methicillin-resistant Staphylococcus aureus (MRSA) is a principal contributor to mortality and morbidity attributable to antimicrobial resistance. Many MRSA strains are able to invade host cells, thereby further evading antibiotic treatment. Previously, indolocarbazole GW296115X was identified as a hit compound with host-directed activity against intracellular MRSA. This study evaluates the efficacy and selectivity of indolocarbazoles as potential host-directed therapy against intracellular MRSA. Furthermore, we assessed the interaction between indolocarbazoles and standard-of-care antibiotics.
Methods
Bioluminescent luxBADCE-expressing MRSA was used to evaluate antimicrobial activity in planktonic cultures and HeLa cell intracellular infection models. Drug safety was assessed through lactate dehydrogenase (LDH) release and WST-1 cytotoxicity assays. The interaction between selected indolocarbazoles in combination with vancomycin or daptomycin was determined based on the Bliss independence model.
Results
Indolocarbazoles GW296115X, staurosporine aglycone, CDK4 inhibitor and SB-218078 showed activity against intracellular MRSA with SB-218078 demonstrating the best potency. None of the effective compounds impaired host cell viability, although host cell metabolic activity was affected to various extents. Combining SB-218078 or GW296115X with vancomycin or daptomycin synergistically eradicated both intracellular and extracellular MRSA.
Conclusions
Indolocarbazoles, particularly GW296115X and SB-218078, enhance standard antibiotic efficacy against invasive MRSA and offer potential for host-directed therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Leiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands.
ORCID-Profile: Robin H G A van den Biggelaar
Zitieren
APA
van den Biggelaar, R. H. G. A., Erdkamp, D., de Visser, A. W., van den Eeden, S. J. F., & Saris, A. (2025). Indolocarbazoles as host-directed therapeutics against intracellular infections by methicillin-resistant Staphylococcus aureus. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf198
Vancouver
van den Biggelaar RHGA, Erdkamp D, de Visser AW, van den Eeden SJF, Saris A. Indolocarbazoles as host-directed therapeutics against intracellular infections by methicillin-resistant Staphylococcus aureus. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf198
BibTeX
@article{vandenBiggelaar2025,
author = {van den Biggelaar, Robin H G A and Erdkamp, David and de Visser, Adriëtte W and van den Eeden, Susan J F and Saris, Anno},
title = {Indolocarbazoles as host-directed therapeutics against intracellular infections by methicillin-resistant Staphylococcus aureus},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2025},
doi = {10.1093/jac/dkaf198}
}
EUVIMED